Citations

Showing 10 of 108162 citations.

Gender Differences in Self-perception of Health at a Wellness Center
Sood, Richa , Jenkins, Sarah M. , Sood, Amit , Clark, Matthew M.

Mayo Clinic

American Journal of Health Behavior | October 30, 2019 | Volume: 43 | Issue: 6 | Pages: 1129-1135

10.5993/ajhb.43.6.10 | PMID 31662171 Get It

Objective: Understanding gender differences in self-perception of health (SPH) and self-efficacy can inform the design of tailored programs to improve health behaviors. We aimed to assess gender-specific differences in SPH and self-efficacy for maintaining wellness habits at a work-place wellness center. Methods: A workplace wellness center member survey was conducted in 2016. Information about SPH and self-efficacy to maintain wellness habits was assessed. Data were analyzed to assess gender differences in SPH and self-efficacy. Results: The survey was completed by 2784 members (mean age, 49.2 years; 68.2% women). SPH was similar between genders despite more men reporting health problems such as hypertension, diabetes, high cholesterol, and cigarette smoking. Women had higher self-efficacy about maintaining healthy diet, but the difference was not clinically meaningful. Women had lower self-efficacy in their ability to maintain physical activity. Conclusions: In this large cohort of worksite wellness center members, men and women had similar self-perception of health despite higher disease burden among men. Women had lower self-efficacy in their ability to maintain physical activity level but similar self-efficacy for maintaining healthy diet. These differences may inform the design of tailored wellness programs to meet the needs of both genders.
Tau deposition in young adults with drug‐resistant focal epilepsy
Smith, Kelsey M. , Blessing, Melissa M. , Parisi, Joseph E. , Mandrekar, Jay , Cascino, Gregory D. , Smith, Kelsey M , Britton, Jeffrey W.

Mayo Clinic

Epilepsia | October 30, 2019 | Volume: 60 | Issue: 12 | Pages: 2398-2403

10.1111/epi.16375 | PMID 31663115 Get It

AbstractObjectiveTo evaluate the presence of tau deposition and pathologic features of chronic traumatic encephalopathy (CTE) in young adult patients treated with focal cortical resections for drug‐resistant epilepsy.MethodsSixty consecutive patients who had undergone surgical treatment for drug‐resistant focal epilepsy between 18 and 45 years of age were identified (2010‐2017). Medical records were reviewed to determine clinical factors, including history of head trauma, age at seizure onset, age at surgical resection, seizure type(s) and frequency, imaging findings, and surgical outcome. All formalin‐fixed, paraffin‐embedded blocks from the surgical specimens from each subject were sectioned and stained with hematoxylin and eosin and antibodies to tau (Thermo Fisher Scientific Clone AT8), and examined blindly for tau pathology, including lesions characteristic of CTE.ResultsThe median age at resection was 29.5 years (range = 19‐45). A history of head trauma was reported in 19 patients. Although none of the patients had pathological findings characteristic of CTE, 23 patients (38%) demonstrated tau‐immunoreactive lesions, including neurites, neurofibrillary pretangles, neurofibrillary tangles, subpial tau, and/or glial tau. In 4 of the 23 patients (7% of the cohort; 17% of those with tau pathology), substantial tau burden was identified. Three of these 4 patients had no significant history of head trauma; 1 patient had multiple sports‐related concussions. No specific clinical factors correlated with the presence of tau pathology.SignificanceTau‐immunoreactive lesions were found in 38% of 60 patients who underwent a focal cortical resection for drug‐resistant focal epilepsy. Diagnostic features of CTE were not detected in any patient; however, the pathological evaluation for CTE was limited to a surgical specimen. The prominent and excessive tau deposition in 23 patients (38%) is abnormal in this age group and warrants further investigation.
Proceedings of the 41st Annual Upper Midwest Neuro-Ophthalmology Group Meeting, July 26, 2019, Chicago, Illinois, USA
Mansukhani, Sasha A. , Chen, John J. , Chen, John J

Mayo Clinic

Neuro-Ophthalmology | October 29, 2019 | Volume: 43 | Issue: 6 | Pages: 421-425

10.1080/01658107.2019.1663879 | PMID 32165905 Get It

Tongue Tied after Shoulder Surgery: A Case Series and Literature Review
Kraus, Molly B. , Cain, Rachel B. , Rosenfeld, David M. , Caswell, Renee E., Hinni, Michael L., Molloy, Michael J. , Trentman, Terrence L. , Kraus, Molly B

Mayo Clinic

Case Reports in Anesthesiology | October 29, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-8

10.1155/2019/5392847 | PMID 31781403 Get It

This article presents three cases of cranial nerve palsy following shoulder surgery with general anesthesia in the beach chair position. All patients underwent preoperative ultrasound-guided interscalene nerve block. Two cases of postoperative hypoglossal and one case of combined hypoglossal and recurrent laryngeal nerve palsies (Tapia’s syndrome) were identified. Through this case series, we provide a literature review identifying postoperative cranial nerve palsies in addition to the discussion of possible etiologies. We suggest that intraoperative patient positioning and/or airway instrumentation is most likely causative. We conclude that the beach chair position is a risk factor for postoperative hypoglossal nerve palsy and Tapia’s syndrome.
Faculty Opinions recommendation of Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease.
Caviness, John N.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 29, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.736772008.793566563 Get It

Editorial Comment
Cheney, Scott, Cheney, Scott M

Mayo Clinic

Journal of Urology | October 29, 2019 | Volume: 203 | Issue: 2 | Pages: 309-309

10.1097/01.ju.0000612532.27564.25 | PMID 31661373 Get It

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Rimawi, Mothaffar F. , Rexer, Brent N. , Forero, Andres , Wolff, Antonio C. , Nanda, Rita , Storniolo, Anna Maria , Krop, Ian E. , Nangia, Julie R. , Jiralerspong, Sao , Pavlick, Anne C. , Veeraraghavan, Jamunarani , Angelis, Carmine De , Osborne, C. Kent , Wang, Tao , Wolff, Antonio C , Schiff, Rachel , Hilsenbeck, Susan Galloway , Rimawi, Mothaffar , De Angelis, Carmine , Niravath, Polly Ann , Wang, Tao , Goetz, Matthew P. , Gutiérrez, Carolina , Schiff, Rachel

Mayo Clinic

Clinical Cancer Research | October 29, 2019 | Volume: 26 | Issue: 4 | Pages: 821-827

10.1158/1078-0432.ccr-19-0851 | PMID 31662331 Get It

Abstract Purpose: Prior neoadjuvant trials with 12 weeks of dual anti-HER2 therapy without chemotherapy demonstrated a meaningful pathologic complete response (pCR) in patients with HER2-positive breast cancer. In this trial, we sought to determine whether longer treatment would increase the rate of pCR. Patients and Methods: TBCRC023 (NCT00999804) is a randomized phase II trial combining a Simon phase II design in the experimental arm with a pick-the-winner design, not powered for direct comparison. Women with HER2-positive breast tumors measuring ≥2 cm (median = 5 cm) were randomized in a 1:2 ratio to 12 versus 24 weeks of lapatinib and trastuzumab. Letrozole (along with ovarian suppression if premenopausal) was administered in patients whose tumors were also estrogen receptor (ER) positive. All evaluable patients were assessed for in-breast pCR. Results: Ninety-seven patients were enrolled (33 in 12-week arm and 64 in 24-week arm), of whom 94 were evaluable. Median age was 51 years, and 55% were postmenopausal. Median tumor size was 5 cm, and 65% were ER-positive. The rate of pCR in the 24-week arm was 28% and numerically superior to the 12-week arm (12%). This was driven by increased pCR in the ER-positive subgroup (33% vs. 9%). Study treatment was well tolerated, with grade 1–2 diarrhea and acneiform rash being the most common toxicities. Conclusions: Treatment with dual anti-HER2 therapy for 24 weeks led to a numeric increase in pCR rate in women with HER2-positive breast cancer, without using chemotherapy. If validated, this approach may help identify patients who may benefit from deescalation of therapy.
Clinical and Imaging Characteristics Associated with Color Vision Impairment in Lewy Body Disease
Unger, Robert , Khosravi, Mitra , Flanigan, Patrick Michael , Leverenz, James B. , Tousi, Babak

Mayo Clinic

Journal of Alzheimer's Disease | October 29, 2019 | Volume: 72 | Issue: 4 | Pages: 1233-1240

10.3233/jad-190727 | PMID 31683482 Get It